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The Activity of Caspase-1 Is Increased in Lesional
Psoriatic Epidermis
Claus Johansen1, Kristine Moeller1, Knud Kragballe1 and Lars Iversen1
Caspase-1 belongs to the group of inflammatory caspases and is the activating enzyme for the proinflammatory
cytokine IL-18, a cytokine known to play an important role in the pathogenesis of psoriasis. The purpose of this
study was to determine the expression of caspase-1 in psoriatic skin and the signaling mechanisms involved in
stress-induced activation of caspase-1 and IL-18. Interestingly, increased caspase-1 activity in lesional compared
with non-lesional psoriatic skin was seen. In vitro experiments in cultured human keratinocytes demonstrated
anisomycin-induced, p38 mitogen-activated protein kinase (p38 MAPK)-dependent increased secretion of
procaspase-1 and active caspase-1. Furthermore, anisomycin increased the mRNA expression of IL-18 through a
p38 MAPK-dependent but caspase-1-independent mechanism, reaching a maximum level after 12 hours of
stimulation. Finally, anisomycin caused a rapid (4 hours) increase in the secretion of proIL-18 and active IL-18.
Secretion of active IL-18 was mediated through a p38 MAPK/caspase-1-dependent mechanism, whereas
secretion of proIL-18 was mediated by a p38 MAPK-dependent but caspase-1-independent mechanism. These
data demonstrate that the activity of caspase-1 is increased in psoriatic skin and that IL-18 secretion is regulated
by a p38 MAPK/caspase-1-dependent mechanism, making caspase-1 a potential target in the treatment of
psoriasis.
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INTRODUCTION
Caspases are evolutionary conserved cysteine proteases.
They are synthesized as inactive proenzymes and become
activated following cleavage at specific cleavage sites
(Cohen, 1997). Caspases play important roles not only in
the induction of apoptosis but also in inflammatory processes.
Caspases can be divided into the apoptotic caspases,
including caspase-2, -3, -6, -7, -8, -9, and -10 and the
inflammatory caspases, including caspase-1, -4, and -5
(Martinon and Tschopp, 2004). Caspase-14 belongs to
another subgroup of caspases and has been implicated in
keratinocyte differentiation (Eckhart et al., 2000). Caspase-1
is one of the best characterized caspases and is best known
for its role in inflammation and innate immune responses to
microbial pathogens (Creagh et al., 2003). Caspase-1 is
constitutively expressed as procaspase-1. Cleavage of pro-
caspase-1 to its mature/active form takes place upon
assembly of a complex termed the ‘‘inflammasome’’. To
date, the following two types of inflammasomes have been
identified: the NALP1 (NACHT (NAip (neuronal apoptosis
inhibitory protein), CIITA (MHC class II transcription acti-
vator), HET-E (incompatibility locus protein from podospora
anserina) and TPI (telomerase-associated protein))-, LRR
(leucine-rich repeat)-, and PYD (pyrin domain)-containing)
inflammasome, which comprises caspase-1, caspase-5, and
Asc (apoptosis-associated speck-like protein containing a
caspase recruitment domain) (Martinon et al., 2002; Martinon
and Tschopp, 2004), and the NALP2 and NALP3 inflamma-
somes, which comprises the caspase recruitment domain-
containing protein cardinal, Asc, and caspase-1 (Petrilli et al.,
2005). Processing of procaspase-1 results in the formation of
both active and intermediate cleavage fragments (Yamin
et al., 1996; Hentze et al., 2003). Once activated caspase-1 is
responsible for the processing of the proinflammatory
cytokines IL-1b and IL-18 to their mature forms (Fantuzzi
and Dinarello, 1999). IL-1b and IL-18 plays an important role
in host defense against a variety of pathogens. Thus, caspase-
1-deficient mice exhibit altered susceptibility to several
pathogens (Sansonetti et al., 2000; Tsuji et al., 2004;
Mariathasan et al., 2005), and they are resistant to endotoxic
shock (Li et al., 1995). Given the essential role of caspase-1 in
the processing of IL-1b and IL-18, the signaling mechanisms
underlying caspase-1 activation have been intensively
studied but remain only partially defined. Previously, stress-
induced activation of caspase-1 and IL-18 has been shown to
be mediated through the p38 mitogen-activated protein
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kinase (p38 MAPK) signaling pathway in HaCaT cells (Shimizu
et al., 1999), in myocardial tissue from rats (Wang et al., 2005),
and in plasma from mice (Sekiyama et al., 2005).
p38 MAPK is a kinase known to play a key role in
inflammatory processes, cellular growth, differentiation as
well as cell death, depending on the cell type and stimulus
(Kumar et al., 2003; Zarubin and Han, 2005). Furthermore,
we have previously demonstrated increased activity of p38
MAPK in lesional psoriatic skin compared with non-lesional
psoriatic skin (Johansen et al., 2005b). Psoriasis is an
immune-mediated inflammatory skin disorder characterized
by skin infiltrating lymphocytes causing hyperproliferation
and abnormal differentiation of the keratinocytes (Wrone-
Smith and Nickoloff, 1996; Stern, 1997). It has been
suggested that psoriatic keratinocytes have abnormalities in
expression and/or activation of different transcription factors
as well as abnormalities in several signaling pathways
(McKenzie and Sabin, 2003; Johansen et al., 2005a, b).
IL-18 is a member of the IL-1 cytokine family and was
initially isolated as an IFN-g-inducing factor (Okamura et al.,
1995). IL-18 is a proinflammatory cytokine produced from a
biologically inactive precursor, proIL-18 (Dinarello, 1999,
2000). ProIL-18 is proteolytically activated into an active 18-
kDa mature form by caspase-1, although it has been described
how anti-bacterial peptides can induce IL-18 secretion by a
caspase-1-independent, but p38 MAPK-dependent mechan-
ism in keratinocytes (Niyonsaba et al., 2005). IL-18 is
expressed in many cell types, including Kupffer cells,
macrophages, T cells, B cells, osteoblasts, dendritic cells,
astrocytes, and keratinocytes (Nakanishi et al., 2001).
Furthermore, human keratinocytes have been demons-
trated to constitutively produce and release proIL-18 in vitro
(Mee et al., 2000). Interestingly, it has been reported that the
expression of IL-18 is markedly increased in psoriasis (Naik
et al., 1999; Ohta et al., 2001; Gangemi et al., 2003;
Companjen et al., 2004).
Given that the expression of IL-18 is elevated in psoriasis
and the fact that caspase-1 is the main protein involved in the
activation of IL-18, we examined caspase-1 expression in
psoriatic skin, and the signaling pathways implicated in the
stress-induced activation of IL-18.
In this study, we demonstrate for the first time that the
activity of caspase-1 is increased in lesional psoriatic skin
compared with non-lesional psoriatic skin, whereas no
regulation of the expression of procaspase-1 was seen.
Moreover, in vitro studies conducted in normal cultured
human keratinocytes revealed that the anisomycin-induced
activation of preformed proIL-18 was mediated by a p38
MAPK/caspase-1-dependent mechanism, whereas anisomycin-
induced new synthesis of proIL-18 mRNA was mediated
through p38 MAPK-dependent but caspase-1-independent
mechanism.
RESULTS
Increased caspase-1 activity in psoriatic skin
To investigate the protein level and the activity of caspase-1
in psoriatic skin, whole-cell extracts from keratome biopsies
obtained from lesional and non-lesional psoriatic skin were
isolated. Western blot experiments revealed that the protein
level of the intermediate form of caspase-1 was significantly
increased (6.3-fold as determined by densitometric analysis,
P¼0.0034) in cell extracts from lesional psoriatic skin
compared with non-lesional psoriatic skin from the same
patient. This was seen for all six patients examined (Figure
1a). No changes were seen in the total protein expression
level of procaspase-1 in lesional compared with non-lesional
psoriatic skin (Figure 1a). In separate sets of biopsies taken
from four psoriatic patients (patients 7–10), we further
examined caspase-1 using an antibody directed against the
p10 subunit of caspase-1. These experiments revealed that
also the active p10 subunit of caspase-1 was significantly
increased (3.4-fold, P¼ 0.019) in lesional compared with
non-lesional psoriatic skin (Figure 1b).
In order to determine if the increase in the p10 subunit of
caspase-1 seen in psoriatic skin was paralleled by an
increased processing of IL-18, we analyzed the IL-18 level
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Figure 1. Increased activity of caspase-1 in lesional compared with
non-lesional psoriatic skin. Whole-cell protein extracts were prepared from
keratome biopsies taken from lesional and non-lesional psoriatic skin and
analyzed by Western blotting. The protein extracts (50 mg of protein) were
separated by SDS-PAGE on a 10–20% gradient gel. After electro-blotting, the
separated proteins were probed with an antibody recognizing (a) procaspase-
1 and the intermediate form of caspase-1, (b) the active p10 subunit of
caspase-1, and (c) proIL-18 and mature IL-18. (b) Human active caspase-1
recombinant protein was used as a positive control. Equal protein loading was
assessed by detecting the protein level of b-actin.
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in patients 7–10 using an antibody recognizing both proIL-18
and processed IL-18. As seen in Figure 1c, the active/
processed form of IL-18 was significantly augmented (3.6-
fold, P¼0.011) in lesional compared with non-lesional
psoriatic skin from the same patient, whereas there were no
significant changes in the protein level of proIL-18 between
lesional and non-lesional psoriatic skin (Figure 1c). Equal
protein loading was assessed by detecting the protein level of
b-actin.
P38 MAPK-dependent activation of caspase-1 by anisomycin
To further characterize caspase-1, cultured normal human
keratinocytes were stimulated with the p38 MAPK activator
anisomycin (500 ng/ml) for the indicated time points. By
Western blot experiments, anisomycin was shown to increase
the protein level of the intermediate form of caspase-1 in a
time-dependent manner. After 4 hours of stimulation, there
was a significant and maximal increase in the intermediate
form of caspase-1 of approximately 6.3-fold (P¼ 0.0087). Not
only was the intermediate form of caspase-1 increased in the
extracellular medium after stimulation with anisomycin, but
also the protein level of procaspase-1 was increased
significantly and time dependently, reaching a maximum
level after 4 hours of stimulation with anisomycin compared
with vehicle-treated cells (3.6-fold, P¼0.018) (Figure 2a). No
regulation in the protein level of b-actin was found in the
extracellular medium after stimulation with anisomycin
(Figure 2a). In contrast, the intermediate form of caspase-1
was not changed in the cell lysates after stimulation with
anisomycin. Furthermore, no regulation of procaspase-1 was
seen in the cell lysates of vehicle-treated or anisomycin-
treated keratinocytes (Figure 2a). Stimulation of the keratino-
cytes with 500 ng/ml anisomycin for 4 hours did not lead to a
decrease in cell viability (data not shown).
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Figure 2. Caspase-1 is activated through p38 MAPK by anisomycin in human keratinocytes. (a) Cultured human keratinocytes were stimulated with anisomycin
(500 ng/ml) for the indicated time points. Then protein extracts were isolated from either the cells or the extracellular medium, respectively, and analyzed by Western
blotting. The proteins were separated by SDS-PAGE on a 10–20% gradient gel and probed with an antibody recognizing procaspase-1 and the intermediate form
of caspase-1 or an antibody recognizing b-actin. (b, c) Keratinocytes were preincubated with SB202190 (10mM) for 45 minutes before stimulated with anisomycin
for 4 hours. The protein extracts were then isolated and analyzed by Western blotting using an antibody recognizing procaspase-1 and the intermediate form
of caspase-1 or an antibody recognizing b-actin, or caspase-1 enzymatic activity was assayed using a caspase-1 colorimetric assay kit. All measurements were
performed in doublets. *Po0.01 compared to vehicle-treated keratinocytes. **Po0.01 compared to keratinocytes-stimulated with anisomycin. (d) Cultured
keratinocytes were preincubated with Ac-YVAD-CMK (100mM) for 45 minutes before stimulated with anisomycin (500 ng/ml) for the indicated time points.
The isolated protein extract was analyzed by Western blotting using an antibody recognizing the phosphorylated form of p38 MAPK. Equal protein loading was
confirmed by incubation with an anti-b-actin antibody. Data shown are one representative out of at least four separate experiments.
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To further characterize the p38 MAPK/caspase-1 signaling
pathway, keratinocytes were preincubated with the p38
MAPK inhibitor SB202190 (10 mM) for 45 minutes before
stimulated with anisomycin for 4 hours. As shown in Figure
2b, SB202190 clearly and significantly reduced not only the
anisomycin-induced increase of the intermediate form of
caspase-1 but also the release of procaspase-1 into the
extracellular medium (P¼0.019 and P¼ 0.0271, respec-
tively), indicating that anisomycin regulates caspase-1
through a p38 MAPK-dependent mechanism (Figure 2b).
Also the enzymatic activity of caspase-1 was analyzed in
cultured human keratinocytes stimulated with anisomycin.
Four hours of stimulation with anisomycin significantly
(P¼0.0042) increased the enzymatic activity of caspase-1
as determined using the specific substrate, WEHD-pNA
(Figure 2c). Furthermore, preincubation with SB202190 for
45 minutes significantly (P¼0.01) reduced the anisomycin-
induced caspase-1 enzymatic activity (Figure 2c). In contrast,
the anisomycin-induced p38 MAPK phosphorylation was not
changed after preincubation with the caspase-1 inhibitor,
Ac-YVAD-CMK (100 mM) (Figure 2d). Equal protein loading
was confirmed by assessing the protein level of b-actin.
Anisomycin increases the IL-18 protein level in cultured normal
human keratinocytes
To study the effect of anisomycin on IL-18 protein release,
cultured normal human keratinocytes were stimulated with
anisomycin (500 ng/ml) for different time periods. IL-18
release was then determined in cell-free supernatants by an
IL-18-specific ELISA, recognizing only the cleaved/active
form of IL-18. A low baseline production of IL-18 protein was
detected in vehicle-treated keratinocytes. However, stimula-
tion of the keratinocytes with anisomycin significantly
increased the IL-18 protein release in a time-dependent
manner (Figure 3a). The maximum increase in IL-18 protein
production was seen after 4 hours of stimulation with
anisomycin, where the IL-18 protein level had increased
approximately 9.5-fold (P¼ 0.0036) compared with vehicle-
treated cells. Twenty-four hours after stimulation with
anisomycin, the IL-18 secretion had returned to baseline
(Figure 3a). To examine the effect of anisomycin on proIL-18,
Western blot experiments were performed using an antibody
recognizing both proIL-18 and active IL-18. In the extra-
cellular medium, both proIL-18 and active IL-18 were
increased significantly over time with a maximum increase
of approximately 1.7-fold (P¼0.035) and 5.1-fold
(P¼0.0093), respectively (Figure 3b), seen after 4 hours of
stimulation with anisomycin. Experiments conducted with
protein extracts from the cell lysates revealed that neither
proIL-18 nor active IL-18 expression intracellularly was
regulated by anisomycin (Figure 3b). Equal protein loading
was confirmed by assessing the protein level of b-actin.
The anisomycin-induced IL-18 production is dependent on p38
MAPK and caspase-1 activation
To examine whether the anisomycin-induced IL-18 produc-
tion in cultured human keratinocytes was dependent on p38
MAPK and caspase-1 activation, keratinocytes were preincu-
bated with SB202190 (10 mM) or Ac-YVAD-CMK (100 mM) for
45 minutes before stimulation for 4 hours with anisomycin. In
the extracellular medium, the anisomycin-induced release of
active IL-18 was significantly (P¼ 0.0082) reduced to vehicle
level by SB202190. In addition, preincubating the keratino-
cytes with the caspase-1 inhibitor, Ac-YVAD-CMK, signifi-
cantly (P¼0.0026) reduced the amount of active IL-18
induced by anisomycin, as determined by ELISA (Figure 4a).
In contrast, when preincubating the keratinocytes with the
extracellular signal-regulated kinase 1/2 inhibitor PD98059
(50 mM) no regulation was found on the IL-18 protein release,
indicating that anisomycin induces the release of active IL-18
by a p38 MAPK/caspase-1-dependent but extracellular
signal-regulated kinase 1/2-independent mechanism in cul-
tured human keratinocytes. The secretion of proIL-18 was
also shown to be increased by a p38 MAPK-dependent
mechanism, because preincubation with SB202190 signifi-
cantly (P¼0.021) inhibited the anisomycin-induced secre-
tion of proIL-18, as determined by Western blotting (Figure
4b). In contrast, the caspase-1 inhibitor, Ac-YVAD-CMK, had
no effect on anisomycin-induced secretion of proIL-18
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Figure 3. IL-18 is increased by anisomycin in a time-dependent manner.
Cultured normal human keratinocytes were stimulated with anisomycin
(500 ng/ml) for the indicated time points. (a) The extracellular medium was
isolated, and IL-18 release into the medium was determined by ELISA. Results
represent mean7SD from at least four different experiments. All
measurements were performed in doublets. *Po0.05 compared with vehicle-
treated keratinocytes. (b) Protein was precipitated from the extracellular
medium and redissolved in SDS-PAGE buffer. The release of proIL-18 and
mature IL-18 was measured by Western blotting using an antibody
recognizing both proIL-18 and mature IL-18. Representative results of at least
four separate experiments are shown. Equal loading was confirmed by
incubation with an anti-b-actin antibody.
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(Figure 4b). Equal protein loading was confirmed by assessing
the protein level of b-actin.
Induction of IL-18 mRNA expression by anisomycin is mediated
through the p38 MAPK
To further characterize the p38 MAPK/caspase-1 signaling
pathway in the regulation of IL-18 expression in cultured
normal human keratinocytes, a time course study was
performed. The IL-18 mRNA expression was significantly
increased over time by anisomycin, as determined by
quantitative reverse transcriptase-PCR. The increase in IL-18
mRNA expression was maximal after 12 hours of stimulation
and had increased by approximately 4.5-fold (P¼0.012)
compared with vehicle-treated keratinocytes (Figure 5a).
Twenty-four hours after stimulation with anisomycin, IL-18
mRNA expression had almost returned to baseline. To
examine the role of p38 MAPK and caspase-1 in the
anisomycin-induced IL-18 mRNA expression, cultured nor-
mal human keratinocytes were preincubated with either
SB202190 (10mM) or Ac-YVAD-CMK (100 mM) for 45 minutes
before stimulating the cells with anisomycin for 12 hours. In
cells preincubated with SB202190, the anisomycin-induced
IL-18 mRNA expression was significantly reduced by
approximately 72% (P¼0.0064) compared with vehicle-
treated cells (Figure 5b). In contrast, when preincubating
keratinocytes with the caspase-1 inhibitor, Ac-YVAD-CMK
(100 mM), no regulation in anisomycin-induced IL-18 mRNA
expression was found, demonstrating that IL-18 mRNA
expression is mediated by a p38 MAPK-dependent but
caspase-1-independent mechanism (Figure 5b).
DISCUSSION
Caspase-1 is the converting enzyme required for the cleavage
and maturation of the proinflammatory cytokines IL-18 and IL-
1b, two cytokines believed to play an important role in the
pathogenesis of inflammatory skin diseases like psoriasis
(Cooper et al., 1990; Le and Abbenante, 2005; Tak et al., 2006).
In this study, we present three essential and novel findings.
First, we demonstrate that the mature/active form of caspase-1
is significantly augmented in lesional psoriatic skin compared
with non-lesional psoriatic skin. In contrast, no regulation of
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procaspase-1 between lesional and non-lesional psoriatic skin
was found. Secondly, anisomycin increased the secretion of
procaspase-1 and proIL-18 by a p38 MAPK-dependent
mechanism in cultured normal human keratinocytes. Finally,
the anisomycin-induced IL-18 mRNA expression in human
keratinocytes was mediated through a p38 MAPK-dependent
but caspase-1-independent mechanism.
Previous studies have demonstrated p38 MAPK to be
involved in the maturation/activation of caspase-1, leading to
activation of IL-18 (Shimizu et al., 1999; Sekiyama et al.,
2005; Wang et al., 2005). Furthermore, the p38 MAPK is
activated in psoriasis as previously demonstrated by our group
(Johansen et al., 2005b). Therefore, cultured human keratino-
cytes were stimulated with anisomycin in order to characte-
rize the 38 MAPK/caspase-1/IL-18 signaling pathway. We
demonstrate here that the anisomycin-induced maturation/
activation of caspase-1 and IL-18 in cultured normal human
keratinocytes is mediated by a p38 MAPK-dependent
mechanism. However, our data further showed that not only
was the active form of caspase-1 and IL-18 increased after
stimulation with anisomycin, but also the levels of procas-
pase-1 and proIL-18 were increased in the extracellular
medium by a mechanism involving the p38 MAPK. Secretion
of procaspase-1 and proIL-18 from the keratinocytes is a novel
and interesting finding indicating that the extracellular
environment in the epidermis may be metabolically active
in inflammatory skin diseases. Interestingly, no regulation of
caspase-1 and IL-18 was found in the cell lysate between
vehicle-treated and anisomycin-treated keratinocytes.
By quantitative reverse transcriptase-PCR, we demons-
trated a steady basal level of IL-18 mRNA expression in
cultured human keratinocytes. This finding is consistent with
that of previous studies demonstrating that human keratino-
cytes are capable of synthesizing IL-18 mRNA even in non-
stimulated conditions (Naik et al., 1999; Mee et al., 2000). In
contrast to the rapid induction of extracellular proIL-18 and
active IL-18 seen after 4 hours of stimulation, the anisomycin-
induced mRNA expression of IL-18 in cultured human
keratinocytes was seen after 6 hours of stimulation with a
maximal induction after 12 hours of stimulation. Furthermore,
using an inhibitor directed against p38 MAPK, the anisomy-
cin-induced IL-18 mRNA expression was significantly in-
hibited, whereas preincubation with a caspase-1 inhibitor
had no effect on the anisomycin-induced IL-18 mRNA
expression. These data indicate that IL-18 is regulated by
two different mechanisms by the p38 MAPK: by a rapid
mechanism at the post-transcriptional and post-translational
level where proIL-18 is processed to its active form by a p38
MAPK/caspase-1-dependent mechanism, and by a more
postponed mechanism where IL-18 is regulated at
the transcriptional level by a p38 MAPK-dependent but
caspase-1 independent mechanism.
We also found that both the intermediate form and the
active p10 subunit of caspase-1 were significantly increased
in lesional psoriatic skin compared with non-lesional
psoriatic skin. This is in agreement with a previous study by
Yamanaka et al. (2000). They used transgenic mice over-
expressing skin-specific caspase-1, and they showed that the
epidermis around skin ulcers in these mice revealed psoriasis-
like changes including parakeratosis. Furthermore, the skin
and sera of these mice showed elevated levels of mature IL-
18 and IL-1b (Yamanaka et al., 2000).
We demonstrate here that the IL-18 expression is regulated
by the p38 MAPK at both the transcriptional and post-
transcriptional level. Furthermore, the activity of caspase-1 is
highly increased in lesional psoriatic skin compared with
non-lesional psoriatic skin. These data together with previous
data from our group showing that the p38 MAPK signaling
pathway is dysregulated in psoriatic skin (Johansen et al.,
2005b, 2006; Funding et al., 2006) strongly indicate that the
p38 MAPK/caspase-1 signaling pathway plays an essential
role in the pathogenesis of psoriasis.
The control of caspase-1 activation and subsequent
processing and maturation of IL-18 and IL-1b is critical for
the regulation of inflammatory conditions in vivo. Under-
standing the mechanisms underlying the activation of
caspase-1 and IL-18 by stress stimuli may contribute to new
therapies for the treatment of inflammatory diseases. In this
study, we demonstrated that both the unprocessed and the
processed/active forms of caspase-1 and IL-18 were induced
post-transcriptionally in cultured normal human keratino-
cytes after stimulation with anisomycin by a p38 MAPK-
dependent mechanism. Furthermore, in vivo studies showed
significantly increased levels of active caspase-1 in lesional
compared with non-lesional psoriatic skin. The p38 MAPK/
caspase-1 signaling pathway may therefore be a new target in
the treatment of psoriasis.
MATERIALS AND METHODS
Biopsies
Keratome biopsies were obtained from lesional and non-lesional
plaque-type psoriatic skin taken from the center of a plaque from
patients with moderate to severe chronic stable plaque psoriasis from
either the upper or lower extremities. For each patient, biopsies were
taken from only one anatomical site. Biopsies were taken as paired
samples, and biopsies from non-lesional psoriatic skin were taken
from the same body region as biopsies from lesional psoriatic skin in
a distance of at least 5 cm from a lesional plaque. In this study, the
ZimmerTM Electronic Dermatome (Zimmer Orthopaedic, Dover, OH)
was used. The dermatome was adjusted according to the degree of
infiltration, as evaluated clinically. When non-lesional biopsies were
obtained, the depth of cut was reduced.
This study was conducted according to the Declaration of
Helsinki Principles. The local ethical committee of Aarhus approved
all described studies. Informed consent was obtained from each
patient.
Cell cultures
Normal adult human keratinocytes were obtained by trypsinization
of skin samples from patients undergoing plastic surgery as described
previously (Kragballe et al., 1985). Second-passage keratinocytes
were grown in K-SFM (Gibco, Invitrogen, Carlsbad, CA). Twenty-
four hours before stimulation with anisomycin, the medium was
changed to keratinocyte basal medium (the same as K-SFM but
without growth factors), in which the cells were stimulated. In some
experiments, the keratinocytes were pretreated with the caspase-1
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inhibitor, Ac-YVAD-CMK (100 mM), the extracellular signal-regu-
lated kinase 1/2 inhibitor PD98059 (50 mM), or the p38a/b inhibitor
SB202190 (10 mM) for 45 minutes before stimulation. Cells were
grown at 371C and 5% CO2 in an incubator.
Lactate dehydrogenase release membrane integrity assay
Lactate dehydrogenase released from cells with compromised
membranes was assayed using the CytoTox-OneTM Homogeneous
Membrane Integrity Assay (Promega, Madison, WI). Keratinocytes,
10,000 cells per well in 96-well plates, were stimulated with
anisomycin or vehicle for 2, 4, 6, and 24 hours, after which 100 ml of
CytoTox-One Reagent was added to each well and the reaction was
allowed to proceed for 10 minutes before addition of 50 ml/well stop
solution. Fluorescence was recorded at a wavelength of 590 nm
using Fluoroskan Ascent Fl (BIE & Berntsen, Rodovre, Denmark).
Maximum lactate dehydrogenase release control was 2 ml of lysis
solution added to control cells before addition of reagent. Percent
cytotoxicity was calculated as a ratio of 100 experimental/
maximum lactate dehydrogenase release.
Western blot analysis
Total cell extracts were prepared from keratome biopsies as
described previously (Johansen et al., 2006). Briefly, biopsies were
homogenized in lysis buffer and left on ice for 30 minutes. Then the
samples were centrifuged at 10,000 g for 10 minutes at 41C, after
which the supernatant constitute the cell lysate. Cultured human
keratinocytes were lysed as described previously (Johansen et al.,
2003). In brief, cells were lysed in cold lysis buffer (50 mM Tris-HCl,
pH 6.8, 10 mM dithiothreitol, 10 mM b-glycerophosphate, 10 mM
NaF, 0.1 mM sodium orthovanadate, 10% glycerol, 2.5% SDS,
25 mM phenylmethanesulfonylfluoride, and 50 complete (a
protease inhibitor cocktail, (Roche, Mannheim, Germany)). Then
the lysate was centrifuged at 13,000 g for 3 minutes, and the
supernatant was collected and assayed for protein concentration as
described by Bradford (1976). The protein from the extracellular
medium was precipitated with 20% trichloroacetic acid and
redissolved in SDS-PAGE buffer before the protein concentration
was determined by Bradford (1976). Both samples were separated by
SDS-PAGE and blotted onto nitrocellulose membranes. Membranes
were incubated with anti-caspase-1 (cat. no. sc-622), anti-p10
(cat. no. sc-515) (Santa Cruz Biotechnology, Santa Cruz, CA), anti-IL-
18 (Chemicon International Inc., Temecula, CA), anti-phospho-p38
(Cell Signalling Technology, Beverly, MA), or anti-b-actin
(Sigma Chemical Co., St Louis, MO) and detected with anti-rabbit
or anti-mouse IgG-horseradish peroxidase (Dako, Glostrup, Den-
mark) in a standard ECL (enhanced chemiluminescence) reaction
(Amersham/Pharmacia Biotech, Uppsala, Sweden), according
to the manufacturer’s instructions. As a positive control for
active caspase-1, we used human active caspase-1 recombinant
protein (cat. no. CC126, Millipore, Billerica, MA). Densitometric
analysis of the band intensity was carried out using Kodak 1D Image
Analysis Software.
ELISA
IL-18 was measured by a sandwich ELISA using two mAb antibodies
against two different epitopes of human IL-18, according to the
manufacture’s protocol (cat. no. 7620, R&D Systems, Oxon, UK).
The final result was determined by an ELISA reader (Laboratory
systems iEMS Reader MF, Copenhagen, Denmark) at 450 nm. All
measurements were performed in doublets.
Caspase-1 enzymatic activity assay
Caspase-1 enzymatic activity was determined using a caspase-1
colorimetric assay kit, according to the manufacture’s protocol (cat.
no. BF14100, R&D Systems). Briefly, protein from the extracellular
medium was precipitated with 20% trichloroacetic acid and added to
cold lysis buffer. A volume of 50ml of cell lysate was added to 2.5 mM
dithiothreitol and 50ml caspase-1 reaction buffer. Each sample was
added to 200mM caspase-1 substrate, WEHD-pNA, followed by
2 hours of incubation at 371C. The enzymatic activity of caspase-1
was measured on an ELISA reader using a 405 nm wavelength.
RNA isolation
RNA was purified with the SV Total RNA Isolation System
(Promega). Briefly, 175ml of SV RNA Lysis Buffer was added to the
cultured human keratinocytes and lysates prepared by manually
scraping the bottom of the wells. The lysates were transferred to
sterile Eppendorf tubes and kept at 801C until RNA purification.
The lysates were carefully thawed while on ice. A 350 ml portion
of SV RNA Dilution Buffer was added and tubes inverted 10 times to
mix. Samples were then put on a heating block for 3 minutes at 701C
and afterwards centrifuged at 13,000 g at room temperature for
10 minutes. Then the supernatant was isolated and added to 200 ml
of 96% ethanol. The mixture was then transferred to spin baskets
attached to a Vac-Man with Mini-Prep Vacuum Adapters (Promega).
Total RNA was purified according to the vacuum protocol, as
described by the manufacturer. Finally, RNA was dissolved in
RNase/DNase-free water and stored at 80 1C until further use.
Quantitative reverse transcriptase-PCR
For reverse transcription, Taqman Reverse Transcription reagents
(Applied Biosystems, Foster City, CA) were used. Primers and probes
were purchased from Applied Biosystems. IL-18 mRNA expression
was analyzed using Taqman 20 Assays-On-Demand expression
assay mix (assay ID: Hs99999040_m1). The probe was a FAM-
labelled MGB probe with a non-fluorescent quencher. Eucaryotic
18S rRNA was used as housekeeping gene.
Eucaryotic 18S rRNA mRNA expression was determined by using
Taqman 20 Assays-On-Demand expression assay mix (assay ID:
Hs99999901_s1). The probe was a FAM-labelled MGB probe with a
non-fluorescent quencher.
PCR mastermix was Taqman 2 Universal PCR Master Mix, No
AmpErase (Applied Biosystems). Each gene was analyzed in triplicates.
The real-time PCR machine was a Rotorgene-3000 (Corbett
Research, Sydney, Australia). Reactions were run as singleplex.
Relative gene expression levels were determined by using the relative
standard curve method as outlined in User Bulletin no. 2 (ABI Prism
7700 sequencing detection system, Applied Biosystems). Briefly, a
standard curve for each gene was made of 3-fold serial dilutions of
total RNA from cultured human keratinocytes. The curve was then
used to calculate relative amounts of target mRNA in the samples.
Statistical analysis
For statistical analysis, a Student’s t-test was performed. To test for
normal distribution, a probability test was made. A probability of
Po0.05 was regarded as statistically significant.
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